Literature DB >> 6460058

Immunotherapy of a chemically-induced sarcoma in rats: characterization of the effector T cell subset and nature of suppression.

E Fernandez-Cruz, S C Gilman, J D Feldman.   

Abstract

Chemically-induced sarcomas (BC5), established subcutaneously and growing progressively in BN rats, were completely eliminated by i.v. infusion of syngeneic effector cells. The effector cells were generated from BN spleen cells immune to BC5 in a mixed lymphocyte-tumor cell culture (MLTC). Generation of a high yield of effector cells that were efficacious in eliminating BC5 in vivo necessitated: depletion of macrophages from immune spleen populations, before preparation of MLTC; addition back to MLTC of a small number of macrophages from normal spleens to attain a level of 0.5% of the spleen cells in culture; and addition of T cell growth factor on day 5 of MLTC. With these conditions a subset of T cells was expanded. They were blast cells with surface markers W3/25 and Ia, which exhibited no cytotoxic activity in vitro, and probably functioned as a helper or amplifier element in the tumor-bearing host. Effector cells generated in MLTC with BC5, treated with mitomycin C, were specific for BC5 in vivo and did not affect growth of a viral-induced BN tumor.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6460058

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Enhancement of immunity against RSV-induced sarcomas by generation of hapten-reactive helper T lymphocytes.

Authors:  P M Comoglio; M Prat; S Bretti
Journal:  Immunology       Date:  1985-02       Impact factor: 7.397

2.  In vivo and in vitro synergistic antitumor effect of interleukin-2-cultured tumor-bearer spleen cells and immune fresh spleen cells.

Authors:  N Kan; T Okino; M Nakanishi; K Satoh; K Ohgaki; T Tobe
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  The role of host lymphocytes and host macrophages in antitumor reactions after injection of sensitized lymphocytes and tumor target cells into naive mice.

Authors:  H F Dullens; W Vuist; M Van der Maas; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

4.  Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells.

Authors:  R J North
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

5.  In vitro activation of natural killer-like cytotoxicity by specifically in vivo primed T-helper lymphocytes in the rat.

Authors:  V Britten; R A Robins; R W Baldwin
Journal:  Immunology       Date:  1984-05       Impact factor: 7.397

6.  Protection against syngeneic lymphoma by a long-lived cytotoxic T-cell clone.

Authors:  M O Dailey; E Pillemer; I L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

7.  Adoptive immunotherapy of a BALB/c lymphoma by syngeneic anti-DBA/2 immune lymphoid cells: characterization of the effector population and evidence for the role of the host's non-T cells.

Authors:  M P Colombo; M Parenza; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

8.  Modulation of the immunosuppressive effects of splenic macrophages in Fischer rats bearing adenocarcinoma 13762.

Authors:  J Bonaventure; V N Nigam; C A Brailovsky
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

9.  Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. A phase I study.

Authors:  A Balsari; R Marolda; C Gambacorti-Passerini; G Sciorelli; G Tona; E Cosulich; D Taramelli; G Fossati; G Parmiani; N Cascinelli
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

10.  Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2.

Authors:  T Nishimura; Y Togashi; M Goto; H Yagi; Y Uchiyama; Y Hashimoto
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.